Spiramycin

Jump to: navigation, search
Spiramycin
Spiramycin I.png
Clinical data
Synonyms2-[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-{[(2S,3R,4R,5S,6R)-5-{[(2S,5S,6S)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy}-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-10-{[(2R,5S,6R)-5-(dimethylamino)-6-methyloxan-2-yl]oxy}-4-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde
Routes of
administration
oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
NIAID ChemDB
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC43H74N2O14
Molar mass843.053 g/mol
3D model (JSmol)
Solubility in waterInsoluble in water; Very soluble in acetonitrile and methanol; Almost completely(>99.5) in ethanol. mg/mL (20 °C)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Spiramycin

Articles

Most recent articles on Spiramycin

Most cited articles on Spiramycin

Review articles on Spiramycin

Articles on Spiramycin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Spiramycin

Images of Spiramycin

Photos of Spiramycin

Podcasts & MP3s on Spiramycin

Videos on Spiramycin

Evidence Based Medicine

Cochrane Collaboration on Spiramycin

Bandolier on Spiramycin

TRIP on Spiramycin

Clinical Trials

Ongoing Trials on Spiramycin at Clinical Trials.gov

Trial results on Spiramycin

Clinical Trials on Spiramycin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Spiramycin

NICE Guidance on Spiramycin

NHS PRODIGY Guidance

FDA on Spiramycin

CDC on Spiramycin

Books

Books on Spiramycin

News

Spiramycin in the news

Be alerted to news on Spiramycin

News trends on Spiramycin

Commentary

Blogs on Spiramycin

Definitions

Definitions of Spiramycin

Patient Resources / Community

Patient resources on Spiramycin

Discussion groups on Spiramycin

Patient Handouts on Spiramycin

Directions to Hospitals Treating Spiramycin

Risk calculators and risk factors for Spiramycin

Healthcare Provider Resources

Symptoms of Spiramycin

Causes & Risk Factors for Spiramycin

Diagnostic studies for Spiramycin

Treatment of Spiramycin

Continuing Medical Education (CME)

CME Programs on Spiramycin

International

Spiramycin en Espanol

Spiramycin en Francais

Business

Spiramycin in the Marketplace

Patents on Spiramycin

Experimental / Informatics

List of terms related to Spiramycin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Spiramycin is a macrolide antibiotic. It is used to treat toxoplasmosis and various other infections of soft tissues. Although used in Europe, Canada and Mexico,[1] spiramycin is still considered an experimental drug in the United States, but can sometimes be obtained by special permission from the FDA for toxoplasmosis in the first trimester of pregnancy.[2]

Spiramycin has been used in Europe since the year 2000 under the trade name "Rovamycine", produced by Rhone-Poulenc Rorer and Famar Lyon, France and Eczacibasi Ilae, Turkey. It also goes under the name Rovamycine in Canada (distributed by OdanLaboratories), where it is mostly marketed to dentists for mouth infections.

Spiramycin is a 16-membered ring macrolide (antibiotic). It was discovered in 1952 as a product of Streptomyces ambofaciens. As a preparation for oral administration it has been used since 1955, in 1987 also the parenteral form was introduced into practice. The antibacterial action involves inhibition of protein synthesis in the bacterial cell during translocation. Resistance to spiramycin can develop by several mechanisms and its prevalence is to a considerable extent proportional to the frequency of prescription in a given area. The antibacterial spectrum comprises Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium sp., Enterobacteria, pseudomonads and pathogenic moulds are resistant. Its action is mainly bacteriostatic, on highly sensitive strains it exerts a bactericide action. As compared with erythromycin, it is in vitro weight for weight 5 to 20 less effective, an equipotential therapeutic dose is, however, only double. This difference between the effectiveness in vitro and in vivo is explained above all by the great affinity of spiramycin to tissues where it achieves concentrations many times higher than serum levels. An important part is played also by the slow release of the antibiotic from the tissue compartment, the marked action on microbes in sub-inhibition concentrations and the relatively long persisting post-antibiotic effect. Its great advantage is the exceptionally favourable tolerance-gastrointestinal and general. It is available for parenteral and oral administration

References


Linked-in.jpg